
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing meloxicam, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing meloxicam are listed in tablet, capsule, suspension, injection and solution forms.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that compounding pharmacies prepare as topical creams and gels, oral capsules and oral suspensions.
Meloxicam is an enolic acid NSAID with analgesic, anti-inflammatory and fever-reducing properties. It blocks cyclooxygenase (COX-1 and COX-2), the enzymes that make prostaglandins, so less of the signaling chemicals that drive pain, swelling and fever are produced in the tissues. Manufactured meloxicam is sold as oral tablets (originally Mobic, now generics), capsules (Vivlodex and generics) labeled for osteoarthritis pain, an oral suspension, an injection (Qamzova), and a combination tablet with rizatriptan (Symbravo). The tablet label lists FDA-approved uses: osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis in patients at or above the label's weight threshold. No topical meloxicam is manufactured. Prescribers may order meloxicam compounded as a topical cream or gel to apply over a joint, as a capsule in a strength not manufactured, as an oral liquid in a different vehicle, or combined with other actives. Compounded meloxicam preparations are not FDA-approved and require a prescription.
Meloxicam carries the NSAID class boxed warning: NSAIDs raise the risk of serious cardiovascular thrombotic events, including heart attack and stroke, which can be fatal, and of serious stomach and intestinal bleeding, ulcers and perforation; meloxicam is contraindicated around coronary artery bypass graft surgery. Other label warnings cover liver injury, new or worsened high blood pressure, heart failure and fluid retention, kidney injury and high potassium, anaphylaxis, serious skin reactions including DRESS, and a warning to avoid use at about 30 weeks of pregnancy or later and to limit use between about 20 and 30 weeks because of fetal kidney problems and low amniotic fluid. Meloxicam adds to bleeding risk with warfarin, aspirin, SSRIs and SNRIs; it can blunt ACE inhibitors, ARBs, beta blockers and diuretics and worsen kidney function with them; and it raises lithium levels and the toxicity of methotrexate, cyclosporine and pemetrexed. People who have had asthma, hives or an allergic reaction after aspirin or another NSAID should not use it. No human data on meloxicam in breast milk exist; a drugs.com breastfeeding review notes other agents may be preferred, especially for a newborn or preterm infant. For heartburn, diarrhea or swelling, talk to your prescriber or pharmacist; seek care right away for black or bloody stools, chest pain, shortness of breath, slurred speech, a blistering rash or yellow eyes.
Meloxicam inhibits COX-1 and COX-2, lowering peripheral prostaglandin synthesis. Oral absolute bioavailability is 89 percent, with a prolonged absorption phase (peak at about 4 to 5 hours fasted) and a second peak at 12 to 14 hours consistent with enterohepatic recycling; the oral suspension is bioequivalent to the tablet. Meloxicam is about 99.4 percent bound to plasma albumin, volume of distribution is about 10 L, and synovial fluid concentrations run 40 to 50 percent of plasma. It is extensively metabolized, chiefly by CYP2C9 with a minor CYP3A4 contribution, to inactive metabolites excreted equally in urine and feces; mean elimination half-life is 15 to 20 hours. Labeled indications (tablets and oral suspension): osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis; meloxicam capsules (Vivlodex and generics): osteoarthritis pain. Prescribers have ordered compounded topical meloxicam for localized musculoskeletal pain; published support is limited to in vitro skin permeation work (Mohammadi-Samani et al., Iran J Basic Med Sci 2014). Dosing and vehicle are per prescriber. Monitoring: blood pressure, renal function and electrolytes, especially with RAAS inhibitors or diuretics; CBC and liver enzymes with chronic use; GI bleeding signs; lithium and methotrexate levels. Not a controlled substance.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally